KRAS and cancer: Human cancer genomics data also provides evidence of the oncogenicity of G12R and G13R substitutions in RAS proteins: KRASG12R accounts for >10% of KRAS-driven PDACs (Supplementary Fig. 15c and Supplementary Data 4), while HRASG13R is the fourth most frequent HRAS mutation in human cancers and NRASG13R is common in colorectal cancers1,8,62.